Mackey, who plans to retire from Whole Foods on September 1, teased a second act. While bemoaning the lack of help patients get in making impactful lifestyle changes, he vowed to "do something about it" and said an announcement is forthcoming.
MedCity INVEST 2022 at The Ritz Carlton Chicago is a 3 day gathering with numerous opportunities for in-person networking and learning around the latest technologies and investment trends from VCs and successful entrepreneurs.
ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company's process for developing and manufacturing RNA therapies borrows from techniques used in the technology sector.
Recently, the ONC revealed its most ambitious healthcare interoperability effort to date with the Trusted Exchange Framework and Common Agreement (TEFCA). It outlines a common set of principles, terms, and conditions to support the overarching goal of establishing a universal floor for health data interoperability across the country.
Flume Health offers a platform for customized health plan administration for insurers who want to develop customized health plans to target certain populations. The company says it can bring tailored plans to the point of launch in just six months.
Bristol Myers Squibb bet more than $1.8 billion that Nektar Therapeutics' drug could be combined with the pharma giant's Opdivo to expand the reach of that drug to more patients. The drug combination has failed its first Phase 3 in advanced melanoma; separate studies in kidney and bladder cancers are ongoing.
In our first in-person event in two years, the MedCity INVEST conference March 28-30 at the Ritz Carlton Hotel in Chicago, there will be many opportunities to connect with startups, investors and potential collaboration partners.
No comments